H James Wedner, MD
Allergy & Immunology · Saint Louis, MONPI 1386661809
Payments from drug & device makers
Across 1,140 payments — averaging $2055.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$442K
- GSK$431K
- Grifols Therapeutics LLC$323K
- Biomarin Pharmaceutical Inc.$262K
- Biocryst Pharmaceuticals, Inc.$175K
- Grifols Biologicals LLC$152K
- plus $558K from 25 others
What the payments were for
- Consulting fees$71,03317%
- Speaking & faculty fees$298,39571%
- Travel & lodging$37,9919%
- Food & beverage$12,0513%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 453 | $441,600 |
| GSK | 130 | $431,398 |
| Grifols Therapeutics LLC | 29 | $323,203 |
| Biomarin Pharmaceutical Inc. | 14 | $261,635 |
| Biocryst Pharmaceuticals, Inc. | 42 | $175,187 |
| Grifols Biologicals LLC | 39 | $152,455 |
| Shire North American Group Inc | 43 | $109,815 |
| CSL Behring | 74 | $80,960 |
| Blueprint Medicines Corporation | 66 | $75,778 |
| Genentech USA, Inc. | 64 | $74,616 |
| Ionis Pharmaceuticals, Inc. | 20 | $42,156 |
| Genentech, Inc. | 13 | $25,676 |
| Astrazeneca UK Limited | 12 | $21,763 |
| Octapharma USA, Inc. | 6 | $21,350 |
| Grifols USA, LLC | 19 | $20,140 |
| Biocryst US Sales Co., LLC | 30 | $19,393 |
| AstraZeneca | 17 | $16,411 |
| Sun Pharmaceutical Industries Inc. | 11 | $14,712 |
| Eli Lilly | 1 | $12,434 |
| Regeneron Healthcare Solutions, Inc. | 17 | $12,069 |
| Pharming Healthcare, Inc. | 17 | $4,984 |
| Sanofi | 9 | $2,749 |
| Sanofi US Services Inc. | 1 | $1,330 |
| Grifols Shared Services North America, Inc. | 1 | $950 |
| Cycle Pharmaceuticals Inc | 1 | $758 |
| Galderma Laboratories, L.p. | 1 | $117 |
| Pfizer | 4 | $67 |
| Bio Products Laboratory USA, Inc. | 3 | $57 |
| Novartis | 1 | $44 |
| Mylan Specialty L.p. | 1 | $15 |
| Organon | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,343,822 in reported general payments places this provider in the 95th percentile of 61 allergy & immunology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KalbitorEcallantide | 15 | $4,488,239 |
| TakhzyroLanadelumab-Flyo | 35 | $1,421,210 |
| AyvakitAvapritinib | 23 | $977,975 |
| HaegardaC1 Esterase Inhibitor | 13 | $638,815 |
| RuconestC1 Esterase Inhibitor, Recomb | 11 | $495,537 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 50 | $334,622 |
| IcatibantIcatibant Acetate | 34 | $314,225 |
| Dupixent SyringeDupilumab | 62 | $234,338 |
| NucalaMepolizumab | 15 | $64,097 |
| Dupixent PenDupilumab | 14 | $52,225 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $49,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $47,155 |
| XolairOmalizumab | 15 | $44,537 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,272 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $14,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Shire North American Group IncKalbitor | $109,815 | $4,488,23915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $441,600 | $1,421,21035 claims |
| Blueprint Medicines CorporationAyvakit | $75,778 | $977,97523 claims |
| CSL BehringHaegarda, Hizentra | $80,960 | $973,43663 claims |
| Pharming Healthcare, Inc.Ruconest | $4,984 | $495,53711 claims |
| GSKNucala, Breo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $431,398 | $168,761175 claims |
| Genentech, Inc.Xolair | $25,676 | $44,53715 claims |
| AstraZenecaSymbicort | $16,411 | $14,57238 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $758 | $6,45625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 allergy & immunology providers in Missouri.
Other allergy & immunology in Saint Louis
- Jeffrey TillinghastSaint Louis$11M
- Peggy KendallSaint Louis$895K
- Barbara JostSaint Louis$470K
- Phillip KorenblatSaint Louis$453K
- Manoj WarrierSaint Louis$316K
- Maya JerathSaint Louis$129K
- Jennifer MonroySaint Louis$123K
- Aaron Ver HeulSaint Louis$100K
- Zhen RenSaint Louis$45K
- Khaled Abdel HamidSaint Louis$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.